Table 1 |
|||||
|
Quantification of lymphocytic infiltrates in the salivary glands of gene-delivered mouse groups |
|||||
|
Disease stage |
Salivary glands |
Lacrimal glands |
|||
|
Treatment |
LF |
Meana |
LF |
Mean |
|
|
|
|||||
|
Saline |
5/6b (83%)c |
2.3 ± 1.5 |
4/6 (67%) |
2.8 ± 1.3 |
|
|
|
|||||
|
Pre-disease |
Lac-Z |
7/7 (100%) |
3.0 ± 2.4 |
6/7 (86%) |
1.5 ± 0.7 |
|
IL-27 |
6/7 (86%) |
4.3 ± 2.2 |
2/7d (29%) |
2.0 ± 1.4 |
|
|
|
|||||
|
Clinical disease |
Lac-Z |
7/7 (100%) |
3.4 ± 2.4 |
4/7 (57%) |
2.5 ± 1.0 |
|
IL-27 |
7/7 (100%) |
3.4 ± 1.3 |
2/7 (29%) |
4.5 ± 5.0 |
|
|
|
|||||
|
aMean lymphocytic foci (LF) score of each gland in mouse ± standard error of the mean per histological salivary gland section; bnumber of mice; cpercentage of mice; dP < 0.05 by chi-squared test. IL-27, rAAV2-IL27-treated groups; LacZ, rAAV2-LacZ-treated groups; saline, saline-treated groups. |
|||||
|
Lee et al. Arthritis Research & Therapy 2012 14:R172 doi:10.1186/ar3925 |
|||||
